A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A
Trial Summary
What is the purpose of this trial?
This trial observes the real-world use of efanesoctocog alfa in patients with hemophilia A in the US and Japan. Efanesoctocog alfa helps blood clot properly by replacing a missing protein. The study will collect data on its effectiveness and safety during routine medical visits over several years.
Research Team
Clinical Sciences & Operations
Principal Investigator
Sanofi
Eligibility Criteria
Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Enrollment
Participants are enrolled in the study after the introduction of efanesoctocog alfa in the hemophilia treatment landscape
Follow-up
Participants are monitored for safety and effectiveness of efanesoctocog alfa
Treatment Details
Find a Clinic Near You
Who Is Running the Clinical Trial?
Sanofi
Lead Sponsor
Paul Hudson
Sanofi
Chief Executive Officer since 2019
Degree in Economics from Manchester Metropolitan University
Christopher Corsico
Sanofi
Chief Medical Officer
MD from Cornell University, MPH in Chronic Disease Epidemiology from Yale University